Who makes Treatment with A319?

Treatment with A319 is developed by Shanxi Bethune Hospital.

What development phase is Treatment with A319 in?

Treatment with A319 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Treatment with A319

Shanxi Bethune Hospital · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Treatment with A319
Sponsor	Shanxi Bethune Hospital
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) (NA)
Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis (EARLY_PHASE1)
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Treatment with A319 CI brief — competitive landscape report
Treatment with A319 updates RSS · CI watch RSS
Shanxi Bethune Hospital portfolio CI